Simvastatin vs therapeutic lifestyle changes and supplements: Randomized primary prevention trial

被引:63
作者
Becker, David J. [1 ]
Gordon, Ram Y. [1 ]
Morris, Patti B. [1 ]
Yorko, Jacqueline [1 ]
Gordon, Y. Jerold [2 ]
Li, Mingyao [3 ]
Iqbal, Nayyar [4 ]
机构
[1] Univ Penn Hlth Syst, Chestnut Hill Hosp, Div Cardiol, Philadelphia, PA USA
[2] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA
[3] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[4] Univ Penn, Philadelphia VA Med Ctr, Div Endocrinol, Philadelphia, PA 19104 USA
关键词
D O I
10.4065/83.7.758
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: To compare the lipid-lowering effects of an alternative regimen (lifestyle changes, red yeast rice, and fish oil) with a standard dose of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin). PATIENTS AND METHODS: This randomized trial enrolled 74 patients with hypercholesterolemia who met Adult Treatment Panel III criteria for primary prevention using statin therapy. All participants were randomized to an alternative treatment group (AG) or to receive simvastatin (40 mg/d) in this open-label trial conducted between April 1, 2006, and June 30, 2006. The alternative treatment included therapeutic lifestyle changes, Ingestion of red yeast rice, and fish oil supplements for 12 weeks. The simvastatin group received medication and traditional counseling. The primary outcome measure was the percentage change in low-density lipoprotein cholesterol (LDL-C). Secondary measures were changes in other lipoproteins and weight loss. RESULTS: There was a statistically significant reduction in LDL-C levels in both the AG (-42.4%+/- 15%) (P <.001) and the simvastatin group (-39.6%+/- 20%) (P <.001). No significant differences were noted between groups. The AG also demonstrated significant reductions in triglycerides (-29% vs -9.3%; 95% confidence interval, -61 to -11.7; P=.003) and weight (-5.5% vs -0.4%; 95% confidence interval, -5.5 to -3.4; P <.001) compared with the simvastatin group. CONCLUSION: Lifestyle changes combined with ingestion of red yeast rice and fish oil reduced LDL-C in proportions similar to standard therapy with shrivastatin. Pending confirmation in larger trials, this multifactorial, alternative approach to lipid lowering has promise for a subset of patients unwilling or unable to take statins.
引用
收藏
页码:758 / 764
页数:7
相关论文
共 44 条
  • [1] Persistence of use of lipid-lowering medications - A cross-national study
    Avorn, J
    Monette, J
    Lacour, A
    Bohn, RL
    Monane, M
    Mogun, H
    LeLorier, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18): : 1458 - 1462
  • [2] BARNES PM, 2004, ADV DATA, V27, P1, DOI DOI 10.1016/J.SIGM.2004.07.003
  • [3] Safety considerations with omega-3 fatty acid therapy
    Bays, Harold E.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (6A) : 35C - 43C
  • [4] Berglund L, 1999, AM J CLIN NUTR, V70, P992
  • [5] Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia - A randomized controlled trial
    Berthold, HK
    Unverdorben, S
    Degenhardt, R
    Bulitta, M
    Gouni-Berthold, I
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19): : 2262 - 2269
  • [6] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS - 2-YEAR EFFICACY AND SAFETY FOLLOW-UP
    BRADFORD, RH
    SHEAR, CL
    CHREMOS, AN
    DUJOVNE, CA
    FRANKLIN, FA
    GRILLO, RB
    HIGGINS, J
    LANGENDORFER, A
    NASH, DT
    POOL, JL
    SCHNAPER, H
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1994, 74 (07) : 667 - 673
  • [7] Lipid disorders - Justification of methods and goals of treatment
    Braunstein, JB
    Cheng, A
    Cohn, G
    Aggarwal, M
    Nass, CM
    Blumenthal, RS
    [J]. CHEST, 2001, 120 (03) : 979 - 988
  • [8] Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators -: The Study on Omega-3 Fatty acids and ventricular Arrhythmia (SOFA) randomized trial
    Brouwer, IA
    Zock, PL
    Camm, AJ
    Böcker, D
    Hauer, RNW
    Wever, EFD
    Dullemeijer, C
    Ronden, JE
    Katan, MB
    Lubinski, A
    Buschler, H
    Schouten, EG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (22): : 2613 - 2619
  • [9] Evaluation of the antihyperlipidemic properties of dietary supplements
    Caron, MF
    White, CM
    [J]. PHARMACOTHERAPY, 2001, 21 (04): : 481 - 487
  • [10] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497